Damaged telomeres and telomerase in liver scarring and liver cancer

Telomere Dysfunction and Telomerase Reactivation in the Etiology and Progression of Liver Cancer

NIH-funded research Utah State Higher Education System--University of Utah · NIH-11471612

Using human stem-cell models, researchers look at how short telomeres and telomerase changes can lead to liver scarring and liver cancer for people with telomere-related risks.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUtah State Higher Education System--University of Utah NIH-funded
Lab location1 site (Salt Lake City, United States)
Project IDNIH-11471612 on NIH RePORTER

What this research studies

From a patient perspective, the team uses human pluripotent stem cells engineered to carry telomerase or telomere defects to grow different types of liver cells in the lab. They compare cells with normal telomeres to cells with short or mutated telomeres to see how DNA damage builds up and which cell types fail. The project also examines common TERT promoter mutations that reactivate telomerase to understand how that change may drive cell transformation toward cancer. The goal is to map the signaling steps from telomere damage to fibrosis and hepatocellular carcinoma so researchers can target those steps in future tests and therapies.

Who could benefit from this research

Good fit: People with inherited telomerase or telomere mutations, unexplained early liver fibrosis, or a high risk of hepatocellular carcinoma would be most relevant to this line of research.

Not a fit: Patients whose liver disease is caused by factors unrelated to telomere biology, or those needing immediate clinical treatment rather than basic research, may not benefit directly from this project.

Why it matters

Potential benefit: If successful, this work could reveal why telomere damage leads to liver fibrosis and cancer and point to targets for earlier detection or new treatments.

How similar studies have performed: Animal models and genetic studies have previously linked telomere shortening and TERT promoter mutations to liver disease, but applying human pluripotent stem-cell models to study the process in human liver cell types is a newer and less-tested approach.

Where this research is happening

Salt Lake City, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Cellular injury
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.